12 Month Price Forecast For CCCC
Distance to CCCC Price Forecasts
CCCC Price Momentum
๐ค Considering C4 Therapeutics (CCCC)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 5:04 AM UTC
CCCC Analyst Ratings & Price Targets
Based on our analysis of 11 Wall Street analysts, CCCC has a bullish consensus with a median price target of $13.00 (ranging from $4.00 to $50.00). Currently trading at $3.37, the median forecast implies a 285.8% upside. This outlook is supported by 6 Buy, 3 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Sudan Loganathan at Stephens & Co., suggesting a 18.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CCCC Analyst Consensus
CCCC Price Target Range
Latest CCCC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CCCC.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Dec 19, 2024 | Wells Fargo | Derek Archila | Overweight | Upgrade | $12.00 |
Nov 18, 2024 | Stephens & Co. | Sudan Loganathan | Equal-Weight | Initiates | $4.00 |
Aug 6, 2024 | BMO Capital | Etzer Darout | Outperform | Reiterates | $20.00 |
May 9, 2024 | Stifel | Bradley Canino | Buy | Maintains | $14.00 |
May 9, 2024 | Wells Fargo | Derek Archila | Equal-Weight | Maintains | $8.00 |
Feb 26, 2024 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $8.00 |
Feb 23, 2024 | Stifel | Bradley Canino | Buy | Reiterates | $13.00 |
Jan 29, 2024 | JP Morgan | Eric Joseph | Neutral | Upgrade | $6.00 |
Dec 13, 2023 | Stifel | Bradley Canino | Buy | Upgrade | $12.00 |
Nov 6, 2023 | Morgan Stanley | Terence Flynn | Equal-Weight | Upgrade | $1.00 |
Nov 3, 2023 | BMO Capital | Etzer Darout | Outperform | Maintains | $16.00 |
Nov 2, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $7.00 |
Oct 9, 2023 | B of A Securities | Chi Fong | Neutral | Maintains | $2.00 |
Aug 9, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $17.00 |
May 30, 2023 | Evercore ISI Group | Gavin Clark-Gartner | Outperform | Maintains | $10.00 |
May 12, 2023 | Morgan Stanley | Terence Flynn | Underweight | Maintains | $3.00 |
May 8, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $25.00 |
Mar 28, 2023 | B of A Securities | Chi Fong | Neutral | Maintains | $5.00 |
Feb 27, 2023 | Morgan Stanley | Terence Flynn | Underweight | Maintains | $5.00 |
Feb 24, 2023 | JP Morgan | Eric Joseph | Underweight | Downgrade | $5.00 |
Stocks Similar to C4 Therapeutics Inc
The following stocks are similar to C4 Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

C4 Therapeutics Inc (CCCC) Financial Data
C4 Therapeutics Inc has a market capitalization of $237.88M with a P/E ratio of -1.3x. The company generates $33.67M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +38.7% quarter-over-quarter, while maintaining an operating margin of -183.9% and return on equity of -46.0%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

C4 Therapeutics Inc (CCCC) Company Overview
About C4 Therapeutics Inc
Develops therapies to degrade disease-causing proteins.
C4 Therapeutics focuses on creating and advancing innovative therapeutic candidates that target and degrade specific disease-causing proteins, primarily for cancer and neurodegenerative conditions. The company generates revenue through strategic collaborations and partnerships with major pharmaceutical companies, which may include milestone payments and royalties based on product commercialization.
C4's lead candidate, CFT7455, is currently in Phase 1/2 trials for multiple hematological malignancies, while other candidates like CFT1946 and CFT8919 are also under development for various cancers. The company, founded in 2015 and based in Watertown, Massachusetts, has established significant partnerships with industry leaders, enhancing its research and development capabilities.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
145
CEO
Mr. Andrew J. Hirsch M.B.A.
Country
United States
IPO Year
2020
Website
www.c4therapeutics.comC4 Therapeutics Inc (CCCC) Latest News & Analysis
C4 Therapeutics (CCCC) shows a hammer chart pattern suggesting potential support after recent declines, alongside positive earnings estimate revisions, indicating a possible trend reversal.
The hammer chart pattern suggests potential price recovery for C4 Therapeutics, while rising earnings estimates indicate improved investor sentiment, possibly leading to a trend reversal.
Cemsidomide combined with dexamethasone in Multiple Myeloma trials achieved a 36% overall response rate and a 45% clinical benefit rate, with responses noted at all dose levels tested.
The promising response rates for Cemsidomide in treating Multiple Myeloma may indicate strong market potential, attracting investor interest in biotech firms developing similar therapies.
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
2 months agoC4 Therapeutics appointed Steve Hoerter to its Board of Directors, enhancing leadership with over 30 years of oncology experience to drive pipeline progress.
The appointment of Steve Hoerter enhances C4T's leadership in oncology, signaling potential growth and success in its drug pipeline, which could positively impact stock performance.
C4 Therapeutics reported a quarterly loss of $0.35 per share, better than the expected loss of $0.40, and an improvement from a loss of $0.55 per share a year ago.
C4 Therapeutics' smaller-than-expected loss indicates improving financial performance, which may boost investor confidence and positively impact the stock price.
C4 Therapeutics (Nasdaq: CCCC) granted 345,600 non-qualified stock options to a new employee on October 28, 2024, as an inducement for employment, per Nasdaq rules.
C4 Therapeutics' stock options grant indicates potential growth and talent acquisition, which could enhance its innovation pipeline and market position, influencing investor sentiment and stock performance.
Mahaney joins with over 25 years of experience in pharmaceuticals and biotech, focusing on drug discovery and enhancing clinical portfolios.
Mahaney's extensive experience in drug discovery and clinical portfolios may enhance the company's innovation pipeline, potentially leading to successful product launches and increased market value.
Frequently Asked Questions About CCCC Stock
What is C4 Therapeutics Inc's (CCCC) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, C4 Therapeutics Inc (CCCC) has a median price target of $13.00. The highest price target is $50.00 and the lowest is $4.00.
Is CCCC stock a good investment in 2025?
According to current analyst ratings, CCCC has 6 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.37. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CCCC stock?
Wall Street analysts predict CCCC stock could reach $13.00 in the next 12 months. This represents a 285.8% increase from the current price of $3.37. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is C4 Therapeutics Inc's business model?
C4 Therapeutics focuses on creating and advancing innovative therapeutic candidates that target and degrade specific disease-causing proteins, primarily for cancer and neurodegenerative conditions. The company generates revenue through strategic collaborations and partnerships with major pharmaceutical companies, which may include milestone payments and royalties based on product commercialization.
What is the highest forecasted price for CCCC C4 Therapeutics Inc?
The highest price target for CCCC is $50.00 from at , which represents a 1,383.7% increase from the current price of $3.37.
What is the lowest forecasted price for CCCC C4 Therapeutics Inc?
The lowest price target for CCCC is $4.00 from Sudan Loganathan at Stephens & Co., which represents a 18.7% increase from the current price of $3.37.
What is the overall CCCC consensus from analysts for C4 Therapeutics Inc?
The overall analyst consensus for CCCC is bullish. Out of 11 Wall Street analysts, 6 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $13.00.
How accurate are CCCC stock price projections?
Stock price projections, including those for C4 Therapeutics Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.